{"id":64501,"date":"2024-09-28T12:04:52","date_gmt":"2024-09-28T12:04:52","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=64501"},"modified":"2026-04-30T10:23:29","modified_gmt":"2026-04-30T10:23:29","slug":"bupcart-xl-150","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/bupcart-xl-150\/","title":{"rendered":"Bupcart-XL 150"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 R\u0103spuns rapid<\/h3>\n

Bupcart-XL 150 (Bupropion 150 mg, extended-release (XL)) is a dopamine-noradrenaline reuptake inhibitor (NDRI) used for major depression, smoking cessation (Zyban indication), and seasonal affective disorder. Distinct profile: stimulating rather than sedating, weight-neutral or weight-reducing, no sexual side effects. XL is once-daily \u2014 better adherence than the BID SR formulation.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Bupcart-XL 150 at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a> \u2014 perioad\u0103 de livrare de 20 de zile lucr\u0103toare sau retrimitem f\u0103r\u0103 costuri suplimentare \u2014 \u0219i se calific\u0103 pentru programul nostru de loialitate pentru clien\u021bi<\/a>. Livr\u0103rile sunt disponibile \u00een majoritatea destina\u021biilor la nivel mondial.<\/p>\n

What Bupcart-XL 150 is and how it works<\/h2>\n

Bupcart-XL 150 is a 150 mg bupropion extended-release (XL) tablet supplied by Cardinal Healthcare. Bupropion is the only widely-prescribed antidepressant whose primary action is dopamine-noradrenaline reuptake inhibition \u2014 not serotonin reuptake. This makes it pharmacologically distinct from SSRIs\/SNRIs\/TCAs and explains its different side-effect signature.<\/p>\n

Traducerea clinic\u0103: bupropionul nu provoac\u0103 disfunc\u021bii sexuale, nu provoac\u0103 cre\u0219tere \u00een greutate (adesea pierdere \u00een greutate) \u0219i este activant \u00een loc de sedativ. Compromisul este o cre\u0219tere semnificativ\u0103 a riscului de convulsii la doze mari, o contraindica\u021bie absolut\u0103 \u00een tulbur\u0103rile de alimenta\u021bie \u0219i o povar\u0103 de insomnie\/anxietate la unii pacien\u021bi.<\/p>\n

Indica\u021bii \u0219i dozaj<\/h2>\n\n\n\n\n\n\n\n\n\n
Indica\u021bie<\/th>\nDoza ini\u021bial\u0103<\/th>\n\u021aint\u0103<\/th>\nMaxim<\/th>\n<\/tr>\n<\/thead>\n
Depresie major\u0103 \u2014 XL<\/td>\n150 mg o dat\u0103 pe zi diminea\u021ba<\/td>\n300 mg o dat\u0103 pe zi<\/td>\n450 mg<\/td>\n<\/tr>\n
Depresie major\u0103 \u2014 SR<\/td>\n150 mg o dat\u0103 pe zi \u00d7 3 zile \u2192 de dou\u0103 ori pe zi<\/td>\n150 mg de dou\u0103 ori pe zi<\/td>\n200 mg de dou\u0103 ori pe zi<\/td>\n<\/tr>\n
\u00cencetarea fumatului<\/td>\n150 mg OD \u00d7 3 zile \u2192 BID (SR) sau 150 mg OD \u00d7 1 s\u0103pt\u0103m\u00e2n\u0103 \u2192 300 mg (XL)<\/td>\n150 mg BID sau 300 mg OD \u00d7 7\u201312 s\u0103pt\u0103m\u00e2ni<\/td>\n\u2014<\/td>\n<\/tr>\n
Tulburare afectiv\u0103 sezonier\u0103 (XL)<\/td>\n150 mg OD \u00eenceput toamn\u0103<\/td>\n300 mg o dat\u0103 pe zi<\/td>\n\u2014<\/td>\n<\/tr>\n
Disfunc\u021bie sexual\u0103 SSRI (off-label)<\/td>\n75\u2013150 mg OD<\/td>\n150 mg OD<\/td>\n300 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Considera\u021bii importante de siguran\u021b\u0103<\/h2>\n
\nRisc de criz\u0103 epileptic\u0103 \u2014 absolut \u0219i dependent de doz\u0103<\/strong><\/p>\n

Bupropion scade pragul convulsiilor. Contraindica\u021bii absolute:<\/strong> orice tulburare convulsiv\u0103, anorexia nervoas\u0103 sau bulimie actual\u0103 sau istoric\u0103, sevraj brusc de la alcool sau sedative. Riscul de convulsii la 300 mg\/zi este de aproximativ 0,1%; la 450 mg\/zi este de aproximativ 0,4% \u2014 o cre\u0219tere de 4 ori. Dozele unice nu trebuie s\u0103 dep\u0103\u0219easc\u0103 150 mg (SR) sau 450 mg total (XL).<\/p>\n<\/div>\n

\nContraindica\u021bie pentru tulbur\u0103ri de alimenta\u021bie<\/strong><\/p>\n

Anorexia \u0219i bulimia sunt contraindica\u021bii absolute \u2014 at\u00e2t datorit\u0103 faptului c\u0103 fiziologia tulbur\u0103rilor de alimenta\u021bie scade pragul convulsiilor (dezechilibru electrolitic, stare cetoacidozic\u0103), c\u00e2t \u0219i datorit\u0103 efectului anorexigen al bupropionului, care poate consolida comportamentul restrictiv. Aceasta este una dintre pu\u021binele contraindica\u021bii clare \u201cnu utiliza\u021bi\u201d \u00een psihiatrie.<\/p>\n<\/div>\n

\nPerioad\u0103 de eliminare MAOI<\/strong><\/p>\n

Perioad\u0103 de eliminare de 14 zile \u00een ambele direc\u021bii. Utilizarea concomitent\u0103 prezint\u0103 risc de criz\u0103 hipertensiv\u0103.<\/p>\n<\/div>\n

\nAvertisment cutie neagr\u0103 privind riscul de suicid (sub 25 de ani)<\/strong><\/p>\n

Toate antidepresivele poart\u0103 un avertisment cutie neagr\u0103 FDA privind cre\u0219terea g\u00e2ndurilor suicidare la pacien\u021bii sub 25 de ani.<\/p>\n<\/div>\n

Efecte secundare frecvente<\/h2>\n